

from 8:00 a.m. to approximately 1:00 p.m. for the review, discussion, and evaluation of individual grant applications. These applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Ms. Mary Plummer, Executive Secretary, NACHHD Council, 6100 Executive Boulevard, Room 5E03, National Institutes of Health, Bethesda, Maryland 20892-7510, Area Code 301, 594-7232, will provide a summary of the meeting and a roster of Council members as well as substantive program information. Individuals who plan to attend the open session and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact Ms. Plummer.

(Catalog of Federal Domestic Assistance Program Nos. [93.864, Population Research, and 93.865, Research for Mothers and Children], National Institutes of Health)

Dated: September 4, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97-23893 Filed 9-9-97; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Deafness and Other Communication Disorders; Amended Notice of Meeting of the National Deafness and Other Communication Disorders Advisory Council

Notice is hereby given of a change in the September 11 meeting of the National Deafness and Other Communication Disorders Advisory Council which was published on August 7, 1997, 62 FR 42587.

The meeting was to have been a closed meeting convened at 1 pm and adjourned at 2 pm on September 11. The meeting has been changed to a partially closed meeting. The Council will meet in open session from 1 pm to approximately 1:45 pm to discuss a meeting of the Work Group on Peer Review. At approximately 1:45 pm the meeting will be closed until adjournment for the review of grant applications.

(Catalog of Federal Domestic Assistance Program No. 93.173 Biological Research

Related to Deafness and Communication Disorders)

Dated: September 4, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97-23896 Filed 9-9-97; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Alcohol Abuse and Alcoholism; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting:

Purpose/Agenda: To review and evaluate grant applications.

Name of Committee: National Institute on Alcohol Abuse and Alcoholism Special Emphasis Panel.

Date of Meeting: September 12, 1997.

Time: 8:30 a.m. to adjournment.

Place of Meeting: Holiday Inn, 5520 Wisconsin Avenue, Bethesda, MD 20815.

Contact Person: Elsie Taylor, 6000 Executive Boulevard, Suite 409, Rockville, MD 20892-7003. 301-443-9787.

The meeting will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C. The proposal and discussions could reveal confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the proposal, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

This notice is being published less than 15 days prior to the meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle.

(Catalog of Federal Domestic Assistance, Program Nos. 93.271, Alcohol Research Career Development Awards for Scientists and Clinicians; 93.272, Alcohol National Research Service Awards for Research Training; 93.273, Alcohol Research Programs; 93.891, Alcohol Research Center Grants; National Institutes of Health)

Dated: September 4, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97-23898 Filed 9-9-97; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive License: For Nucleic Acid-Based Vaccines and Therapeutics

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is a notice in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of a limited field of use exclusive license in the United States to practice the invention embodied in U.S. Patent Application Number 08/286,730 entitled, "Liposomal Delivery System for Nucleic Acids," and its Continuation-In-Part U.S. Patent Application Serial Number 08/522,246, and all related foreign filings (PCT/US95/09867), invented by Alain Thierry formerly of the National Cancer Institute, to Biovector Therapeutics, S.A. of Labage, France. The patent rights in these inventions have been assigned to the United States of America.

DATES: Only written comments and/or applications for a license which are received by NIH on or before December 9, 1997 will be considered.

ADDRESSES: Requests for copies of the subject issued patent and pending patent applications, inquiries, comments and other materials relating to the contemplated license should be directed to: Mr. Larry M. Tiffany, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852; Telephone: (301) 496-7056, ext. 206; Facsimile: (301) 402-0220. A signed Confidentiality Agreement will be required to receive copies of the pending patent applications.

SUPPLEMENTARY INFORMATION: The present invention relates to a liposome composition comprising a bi- or multi-layered membrane surrounding an internal aqueous liposome comprising at least one cationic lipopolyamine and at least one neutral lipid provided in a molar ratio range, said ratio from about .02:1 to 2:1. In addition to the pending composition claims there are also pending rights to methods of preparing the liposome composition, pharmaceutical compositions including the liposome and methods of introducing nucleic acids into cells using the liposome. This invention is advantageous over alternative lipid preparations due to its ability to more